Tal Wanderow is CEO of Vocalis. He and host Bret Kinsella discuss the latest progress behind employing vocal biomarkers to evaluate health conditions and risks. We go into detail about the current work behind tools for diagnosing and monitoring COVID-19 patients. We even explore the ethics of what data patients should have a right to access. Vocalis Health is focused on using vocal biomarkers to identify the likelihood of hospitalization for a variety of conditions and have another product focused on respiratory disease detection and monitoring. Given that background, it's not surprising that the company has taken a prominent role in the healthcare industry response to the coronavirus pandemic.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related